Orlistat: in the prevention and treatment of type 2 diabetes mellitus (Q34458506)

2 August 2017

1 reference

title

Orlistat: in the prevention and treatment of type 2 diabetes mellitus (English)

1 reference

2 August 2017

1 reference

Keating GM

1

1 reference

2 August 2017

Jarvis B

series ordinal

2

1 reference

2 August 2017

publication date

1 January 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

61

1 reference

2 August 2017

issue

14

1 reference

2 August 2017

page(s)

2107-19; discussion 2120-1

1 reference

The prevention and treatment of obesity. Application to type 2 diabetes

2 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200161140-00011

Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200161140-00011

The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200161140-00011

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

12 December 2020

The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers

1 reference

12 December 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers

1 reference

12 December 2020

Is continued weight gain inevitable in type 2 diabetes mellitus?

1 reference

12 December 2020

Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.

1 reference

12 December 2020

Treatment with orlistat reduces cardiovascular risk in obese patients

1 reference

12 December 2020

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study

1 reference

12 December 2020

Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient

1 reference

12 December 2020

Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes

1 reference

12 December 2020

The treatment of obesity in type 2 diabetes mellitus

1 reference

12 December 2020

Long-term effects of modest weight loss in type II diabetic patients

1 reference

12 December 2020

The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers

1 reference

12 December 2020

Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers

1 reference

12 December 2020

Orlistat in the long-term treatment of obesity in primary care settings

1 reference

12 December 2020

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

12 December 2020

Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients

1 reference

12 December 2020

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

1 reference

12 December 2020

Beneficial health effects of modest weight loss

1 reference

12 December 2020

Weight gain as a risk factor for clinical diabetes mellitus in women

1 reference

12 December 2020

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers

1 reference

12 December 2020

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

1 reference

12 December 2020

Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor

1 reference

12 December 2020

Mode of action of orlistat

1 reference

12 December 2020

Orlistat: a review of its use in the management of obesity

1 reference

12 December 2020

Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects

1 reference

12 December 2020

Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers

1 reference

12 December 2020

The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers

1 reference

12 December 2020

Large spectral changes accompany the conformational transition of human pancreatic lipase induced by acylation with the inhibitor tetrahydrolipstatin

1 reference

12 December 2020

Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers

1 reference

12 December 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers

1 reference

12 December 2020

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

1 reference

12 December 2020

Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers

1 reference

12 December 2020

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

1 reference

12 December 2020

Lack of interaction between orlistat and oral contraceptives

1 reference

12 December 2020

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

1 reference

12 December 2020

Co-administration of orlistat and cyclosporine in a heart transplant recipient

1 reference

12 December 2020

Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study

1 reference

12 December 2020

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

1 reference

12 December 2020

The impact of pharmacotherapy on weight management in type 2 diabetes

1 reference

12 December 2020

Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers

1 reference

12 December 2020

The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers

1 reference

12 December 2020

10.2165/00003495-200161140-00011

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1009135396

0 references

1 reference